# Bakhu Pharma Limited (07585370)

> Why UK company 07585370 went into administration, from the administrators' statement filed at Companies House, by companydig. Interactive version: https://companydig.co.uk/company/07585370

- **Status:** Administration ended
- **Administration began:** 2013-10-09
- **Administrators:** Jeremy Mark Willmont
- **Administrators' firm:** Baird Partners
- **Incorporated:** 2011-03-31
- **Location:** London
- **Industry:** 21100 Manufacture of basic pharmaceutical products

## Why it went into administration

- Funding withdrawn / unable to refinance

## From the administrators' statement

The Company was established by Colin Leece and Lee Proctor (‘the Directors’) in March 2011 In June 2011 it acquired selective assets from the administrators of a predecessor company, namely Phoenix Chemicals Limited (“Phoenix”) Both Colin Leece and Lee Proctor were directors of Phoenix and Colin Leece was also a shareholder of Phoenix

Furthermore, Bakhu Limited a company associated by common directorship, purchased the Intellectual Property and certain assets of Phoenix, which were subsequently sold to the Company

The Company focussed on the research, development and the manufacture of high-value pharmaceutical intermediates which were sold into the Statin (cholesteroljowering) drug market The Company's manufacturing site was configured to produce two major statin intermediaries — BHA (Rosuvastatin) and ATS8 (Atorvastatin)

Statement of proposals: https://find-and-update.company-information.service.gov.uk/company/07585370/filing-history/MzA5MDE0NjU2NmFkaXF6a2N4/document?format=pdf&download=0
Companies House register: https://find-and-update.company-information.service.gov.uk/company/07585370

Contains public sector information from Companies House, licensed under the Open Government Licence v3.0.